CIK 0000907654 · Non-accelerated filer<br>Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 363855489
- Phone
- 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,653,308
- in 17 filings, $20.2M under 10b5-1 plans
Net −$20,653,308. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
- Quinlan Paul T −$1.7M General Counsel sold 40% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise 10b5-1 | +8,542 | $12.50 | $107K | 22,761 |
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise 10b5-1 | +1,458 | $34.39 | $50K | 24,219 |
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −500 | $101.98 | $51K | 23,719 |
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −801 | $103.16 | $83K | 22,918 |
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −799 | $104.25 | $83K | 22,119 |
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −6,842 | $105.28 | $720K | 15,277 |
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −958 | $106.18 | $102K | 14,319 |
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Sale 10b5-1 | −100 | $107.00 | $11K | 14,219 |
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −8,542 | 67,834 | ||
| 2026-11-12 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,458 | 55,417 | ||
| 2026-11-12 | BALL KRISTINE M Director | Option exercise 10b5-1 | +18,000 | $6.84 | $123K | 18,000 |
| 2026-11-12 | BALL KRISTINE M Director | Sale 10b5-1 | −1,196 | $102.10 | $122K | 16,804 |
| 2026-11-12 | BALL KRISTINE M Director | Sale 10b5-1 | −1,300 | $103.09 | $134K | 15,504 |
| 2026-11-12 | BALL KRISTINE M Director | Sale 10b5-1 | −2,039 | $104.16 | $212K | 13,465 |
| 2026-11-12 | BALL KRISTINE M Director | Sale 10b5-1 | −10,765 | $105.31 | $1.1M | 2,700 |
| 2026-11-12 | BALL KRISTINE M Director | Sale 10b5-1 | −2,500 | $106.05 | $265K | 200 |
| 2026-11-12 | BALL KRISTINE M Director | Sale 10b5-1 | −200 | $106.99 | $21K | 0 |
| 2026-11-12 | BALL KRISTINE M Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,000 | 53,426 | ||
| 2026-11-02 | Klein Lawrence Otto Chief Executive Officer | Option exercise 10b5-1 | +25,000 | $7.80 | $195K | 948,128 |
| 2026-11-02 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −6,466 | $94.77 | $613K | 941,662 |
Page 1 of 18 · 346 trades